- Home
- BEN vs ROIV Comparison
BEN vs ROIV Comparison
Compare BEN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BEN | ROIV |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BEN | ROIV |
|---|---|---|
| Price | $24.76 | $22.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $24.64 | $24.31 |
| AVG Volume (30 Days) | 4.0M | ★ 6.9M |
| Earning Date | 01-30-2026 | 02-09-2026 |
| Dividend Yield | ★ 5.08% | N/A |
| EPS Growth | ★ 7.28 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $8,770,700,000.00 | $20,329,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.65 | $741.42 |
| P/E Ratio | $28.57 | ★ N/A |
| Revenue Growth | ★ 3.45 | N/A |
| 52 Week Low | $16.25 | $8.73 |
| 52 Week High | $26.25 | $23.91 |
Technical Indicators
Market Signals| Indicator | BEN | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 57.48 |
| Support Level | $25.13 | $22.15 |
| Resistance Level | $26.25 | $23.91 |
| Average True Range (ATR) | 0.58 | 0.72 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 43.24 | 65.65 |
Price Performance
Historical ComparisonAbout BEN Franklin Resources Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.